METHOD OF IDENTIFYING AGENTS THAT AFFECT MATURATION, SURVIVAL AND MYELINATION
The present invention discloses a method of identifying agents that affect maturation and survival of oligodendrocytes or myelination of neuronal cells using ex-vivo differentiated embryonic stem cells.
Latest KADIMASTEM, LTD. Patents:
- METHODS FOR DIFFERENTIATING AND PURIFYING PANCREATIC ENDOCRINE CELLS
- Methods for differentiating and purifying pancreatic endocrine cells
- METHODS OF TREATING ACUTE RESPIRATORY DISTRESS SYNDROME
- DIRECTED DIFFERENTIATION OF ASTROCYTES FROM HUMAN PLURIPOTENT STEM CELLS FOR USE IN DRUG SCREENING AND THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS)
- DIRECTED DIFFERENTIATION OF ASTROCYTES FROM HUMAN PLURIPOTENT STEM CELLS FOR USE IN DRUG SCREENING AND THE TREATMENT OF AMYOTROPHIC LATERIAL SCLEROSIS (ALS)
The invention, in some embodiments thereof, relates to a method of identifying agents that affect maturation and survival of oligodendrocytes or myelination of neuronal cells using ex-vivo differentiated embryonic stem cells.
Myelin, the fatty substance, which encloses certain axons and nerve fibers, provides essential insulation, and enables the conductivity of nerve cells, which transmit electrical messages to and from the brain.
Aberration in myelination can lead to several pathologies in the central nervous system. These include, for example, autoimmune diseases (e.g multiple sclerosis), congenital leukodystrophies (e.g Pelizaeus-Merzbacher, vanishing white matter, adrenoleukodystrophy), infectious diseases (e.g. progressive multifocal leukoencephalopathy, postinflammatory demyelinated lesions), neurodegenerative diseases (e.g. multisystem degeneration), vascular diseases (vascular leukoencephalopathies, subcortical infarcts), neurodegenerative diseases (e.g. amyotrophic lateral sclerosis [ALS], Alzheimer's disease, Parkinson's disease), demyelinative brain or spinal cord trauma or injuries, and possibly neoplasms (e.g. oligodendrio-glioma).
Treatment of these pathologies may be effected by cell replacement therapies, which eventually may allow achieving regional or even global repair of myelin as indicated by experiments in MBP-deficient shiverer mice (e.g. Yandava et al., 1999, Proc Natl Acad Sci USA 96, 7029-34).
Oligodendrocytes extend as many as 50 processes, which wrap around axons to form myelin sheaths. In-vitro and in-vivo, the development of oligodendrocytes proceeds in steps from neural stem cells to bipolar progenitors, then to multipolar precursor cells having several main processes which subsequently arborize and form the multiple branches of the mature cells (Rogister et al., 1999, Mol Cell Neurosci 14, 287-300; Grinspan, 2002, J Neuropathol Exp Neurol 61, 297-306). Early oligodendrocytes precursors (OP) express the PDGF-receptor and later the specific O4 sulfatide marker of pre-oligodendrocytes which persists in ramified immature oligodendrocytes, then the maturating cells express galactocerebrosides (01, GalC) and 2′,3′ cyclic nucleotide 3′ phosphodiesterase (CNP), and at the final stage become postmitotic mature oligodendrocytes that synthesize the myelin membrane components such as proteolipid protein (PLP) and myelin basic protein (MBP).
Until presently, mechanistic studies analyzing human oligodendrocyte differentiation and functional myelination have been based on rodent assays. However the significant differences in gene expression and dominant signaling pathways between rodent and human's oligodendrocyte progenitor cells (OPCs) suggest that such assays may provide false results [Sim, F. J., et al., Neuron Glia Biol 5, 45-55 (2009)].
A co-culture system using brain derived OPCs from human embryos was recently described [Cui, Q. L. et al. Response of human oligodendrocyte progenitors to growth factors and axon signals. J Neuropathol Exp Neurol 69, 930-944]. However, the use of human embryos is problematic, due to lack of reproducibility and poor availability.
U.S. Patent Application No. 20100003751 teaches generation of oligodendrocytes from human embryonic stem cells.
SUMMARY OF THE INVENTIONAccording to one aspect of the present invention, there is provided a method of quantifying an effect of an agent on myelination of neuronal cells, the method comprising:
(a) contacting a population of oligodendrocyte precursor cells (OPCs), the OPCs having been ex-vivo differentiated from embryonic stem cells with the agent; and
(b) quantifying at least one marker of myelination in the OPCs, thereby quantifying the effect of the agent on myelination of neuronal cells.
According to another aspect of the present invention, there is provided a method of quantifying an effect of an agent on maturation, survival or a combination thereof of oligodendrocytes, the method comprising:
(a) contacting a population of oligodendrocyte precursor cells (OPCs), oligodendrocytes or a combination thereof that were ex-vivo differentiated from embryonic stem cells with the agent; and
(b) quantifying at least one marker of maturation, survival or a combination thereof in the oligodendrocytes, thereby quantifying the effect of the agent on maturation, survival or a combination thereof of the oligodendrocytes.
According to some embodiments of the invention, the OPCs express olig1 and olig2 to a greater extent than they express myelin basic protein (MBP).
According to some embodiments of the invention, the OPCs express each of olig1, olig2 or a combination thereof.
According to some embodiments of the invention, the OPCs further express Hes5.
According to some embodiments of the invention, the marker is a polypeptide selected from the group consisting of myelin basic protein (MBP), myelin oligodendrocyte glycoprotein (MOG), galactocerebroside (GalC), myelin associated glycoprotein (MAG), 2′3′-cyclic nucleotide-30-phosphodiesterase (CNP), O4 and proteolipid protein (PLP).
According to some embodiments of the invention, the quantification of the effect of the agent on myelination, maturation, survival, or a combination thereof, is conducted by counting the number of O4 stained cells with at least two processes, the percentage of O4 positive cells, the number of processes per O4 stained cells, the total length of the processes per O4 stained cells, the number of branch points per O4 stained cells, the number of MBP positive cells, calculating the percentage of MBP positive cells or measuring the area of myelin membranes per stained cells or the area of the O4 stained processes.
According to some embodiments of the invention, the agent is a small molecule.
According to some embodiments of the invention, the OPCs are present in a culture comprising neuronal cells.
According to some embodiments of the invention, the neuronal cells are human neuronal cells.
According to some embodiments of the invention, the neuronal cells are rodent neuronal cells.
According to some embodiments of the invention, the culture is devoid of Schwann cells. According to some embodiments of the invention, the Schwann cells are eliminated by 5′-fluoro-2′-deoxyuridine (FUdR)
According to some embodiments of the invention, the method further comprises quantifying an amount of myelination of neuronal cells in the culture comprising neuronal cells.
According to some embodiments of the invention, the quantifying an amount of myelination in the neuronal cells is assessed by analyzing an expression of contactin associated protein 1 (Caspr1) in the neuronal cells.
According to some embodiments of the invention, the quantifying an amount of myelination in the neuronal cells is effected by analyzing an expression of Neurofilament (NF) in the neuronal cells.
According to some embodiments of the invention, the quantifying an amount of myelination in the neuronal cells is assessed by analyzing a juxtaposition of the neuronal cells and myelinating cells.
According to some embodiments of the invention, the method further comprises ex-vivo differentiating embryonic stem cells into the OPCs prior to step (a).
According to some embodiments of the invention, the method further comprises a step of selecting the OPCs according to an expression of a cell surface marker.
According to some embodiments of the invention, the cell surface marker is CD140 (PDGFR alpha) or O4.
According to some embodiments of the invention, the step of selecting is by magnetic sorting or fluorescence activated cell sorting (FACS).
According to some embodiments of the invention, the differentiating is effected by a method comprising:
(a) culturing in a suspension undifferentiated human embryonic stem cells in the presence of retinoic acid and growth factors to generate neurospheres; and
(b) contacting the neurospheres with a growth factor on an adherent substrate.
According to some embodiments of the invention, the method further comprising a step of contacting the neurospheres in a medium being devoid of the growth factor following step (b).
According to some embodiments of the invention, the contacting is effected for 2-3 days.
According to some embodiments of the invention, the undifferentiated human embryonic stem cells are aggregated.
According to some embodiments of the invention, the growth factor is bFGF, EGF or a combination thereof.
According to some embodiments of the invention, the suspension comprises noggin.
According to some embodiments of the invention, the adherent substrate is a matrigel or an extracellular matrix component.
According to some embodiments of the invention, the step (a) is effected for 10-30 days.
According to some embodiments of the invention, the medium is devoid of growth factors comprises noggin
According to some embodiments of the invention, the method further comprises testing the agent which is indicative of upregulating myelination of neuronal cells in-vivo.
According to some embodiments of the invention, the method further comprises testing the agent which is indicative of down-regulating myelination of neuronal cells in-vivo.
According to some embodiments of the invention, the method further comprises manufacturing a pharmaceutical composition comprising the agent which is capable of upregulating myelination of neuronal cells.
According to some embodiments of the invention, the method further comprises manufacturing a pharmaceutical composition comprising the agent which is capable of downregulating myelination of neuronal cells.
According to some embodiments of the invention, the method further comprises testing the agent which is capable of upregulating maturation or survival of oligodendrocytes in-vivo.
According to some embodiments of the invention, the method further comprises testing the agent which is capable of down-regulating maturation or survival of oligodendrocytes in-vivo.
According to some embodiments of the invention, the method further comprises manufacturing a pharmaceutical composition comprising the agent which is capable of upregulating maturation or survival of oligodendrocytes.
According to some embodiments of the invention, the method further comprises manufacturing a pharmaceutical composition comprising the agent which is capable of downregulating maturation or survival of oligodendrocytes.
According to some embodiments of the invention, a pharmaceutical composition comprising an agent identified according to the methods of the present invention is provided.
Unless otherwise defined, all technical and/or scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which the invention pertains. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of embodiments of the invention, exemplary methods and/or materials are described below. In case of conflict, the patent specification, including definitions, will control. In addition, the materials, methods, and examples are illustrative only and are not intended to be necessarily limiting.
The patent or application file contains at least one drawing executed in color. Copies of this patent or patent application publication with color drawing(s) will be provided by the Office upon request and payment of the necessary fee.
Some embodiments of the invention are herein described, by way of example only, with reference to the accompanying drawings and images. With specific reference now to the drawings in detail, it is stressed that the particulars shown are by way of example and for purposes of illustrative discussion of embodiments of the invention. In this regard, the description taken with the drawings makes apparent to those skilled in the art how embodiments of the invention may be practiced.
In the drawings:
The present invention, in some embodiments thereof, relates to a method of identifying agents that affect maturation and survival of oligodendrocytes or myelination of neuronal cells using ex-vivo differentiated embryonic stem cells.
Before explaining at least one embodiment of the invention in detail, it is to be understood that the invention is not necessarily limited in its application to the details set forth in the following description or exemplified by the Examples. The invention is capable of other embodiments or of being practiced or carried out in various ways.
Until presently, mechanistic studies analyzing human oligodendrocyte differentiation and functional myelination have been based on rodent assays. A co-culture system using brain derived OPCs from human embryos was recently described. However, the use of human embryos is problematic, due to lack of reproducibility and poor availability.
The invention is based in part on a novel human-specific differentiation and myelination assay which may be used to quantitatively screen for drugs that affect oligodendrocytes (Ols), their precursors, Oligodendrocyte Progenitor Cells (OPCs) and additionally their functionality in interacting with neuronal axons. This assay is based on the use of reproducible cell lines of Ols or OPCs that are ex-vivo differentiated from human embryonic stem (ES) cells. The cell lines can be stored in liquid nitrogen and thawed when needed.
The invention enables the use of hES derived OPCs (hES-OPCs) for quantitatively screening agents which up-regulate maturation of OPCs into Ols, their survival and myelination.
Quantifying the effect of one agent (noggin) on a cell line of such hES-OPCs was performed by counting the number of O4 positive cells, the number of processes and branch points (Example 2).
Quantifying the effect of a small molecule agent (a gamma secretase inhibitor) was performed by co-culturing the hES-OPC with dorsal root ganglion (DRG) neuronal axons and counting the number of co-localized of MBP positive fibers and Neurofilament positive fibers as compared to non-treated cells (Examples 3 and 4).
Thus, according to one aspect of the present invention there is provided a method of quantifying an effect of an agent on myelination of neuronal cells, the method comprising:
(a) contacting a population of oligodendrocyte precursor cells (OPCs), the OPCs having been ex-vivo differentiated from embryonic stem cells with the agent; and
(b) quantifying at least one marker of myelination in the OPCs, thereby quantifying the effect of the agent on myelination of neuronal cells.
As used herein, the term “myelin” refers to the fatty substance which encloses certain axons and nerve fibers, provides essential insulation, and enables the conductivity of nerve cells which transmit electrical messages to and from the brain.
The phrase “myelination of neuronal cells” refers to the ability of oligodendrocytes (i.e. processes extending therefrom) to wrap around neuronal axons and form myelin sheaths.
As used herein, the term “maturation of OPCs” refers to the maturation or differentiation program of OPCs into myelinating oligodendrocytes.
As used herein, the term “survival” is meant any process by which a cell avoids death. The term survival, as used herein, also refers to the prevention of cell loss as evidenced by necrosis, apoptosis, or the prevention of other mechanisms of cell loss. Increasing survival as used herein indicates a decrease in the rate of cell death by at least 10%, 25%, 50%, 75%, 100%, 200% or more relative to an untreated control. The rate of survival may be measured by counting cells capable of being stained with a dye specific for dead cells (e.g., propidium iodide) in culture.
The cells used in the assay of this aspect of the present invention comprise oligodendrocyte precursor cells which have been ex-vivo differentiated from embryonic stem cells.
It will be appreciated that the OPCs of this aspect of the present invention have the potential to differentiate into a myelinating phenotype (i.e. to increase myelination in-vitro), but are not capable, without further treatment (e.g. in the presence of an agent which induces further differentiation thereof), of myelinating in-vitro.
In this aspect of the invention, the OPCs may also have the following functional phenotypes—a mitotic phenotype (i.e. that can divide and be expanded for three or more passages in culture) and migratory capacities.
The OPCs may comprise an elongated, bipolar or multipolar morphology. Typically, the OPCs can incorporate bromodeoxyuridine (BudR), a hallmark of mitosis.
Examples of OPC marker expression include, but are not limited to, PDGF-receptor, O4 sulfatide marker, Nkx2.2, Sox10, Olig1, Olig2, oligodendrocyte specific protein (OSP), 2′,3′-cyclic nucleotide-3′-phosphodiesterase (CNP), adenomatous polyposis coli (APC); NG2 (Chondroitin sulfate proteoglycan), A2B5, GD3 (ganglioside), nestin, vimentin and E- or PSA-NCAM.
According to a particular embodiment the OPCs of this aspect of the present invention express Olig1 and Olig2 to a greater extent than they express myelin basic protein (MBP) as measured in an identical assay. Such assays include analysis by Immunohistochemistry, RT-PCR and/or Western blot analysis.
As used herein, the term “to a greater extent” is meant between 2 to 20 fold.
According to another embodiment, the OPCs of this aspect of the present invention OPCs express each of olig1, olig2 and Hes5.
As mentioned, the OPCs of this aspect of the present invention are ex-vivo differentiated from embryonic stem cells (ESCs).
For example, human embryonic stem cells can be isolated from human blastocysts or delayed blastocyst stage (as described in WO2006/040763). Human blastocysts are typically obtained from human in-vivo preimplantation embryos or from in-vitro fertilized (IVF) embryos. Alternatively, a single cell human embryo can be expanded to the blastocyst stage. For the isolation of human ES cells the zona pellucida is removed from the blastocyst and the inner cell mass (ICM) is isolated by immunosurgery, in which the trophectoderm cells are lysed and removed from the intact ICM by gentle pipetting. The ICM is then plated in a tissue culture flask containing the appropriate medium which enables its outgrowth. Following 9 to 15 days, the ICM derived outgrowth is dissociated into clumps either by a mechanical dissociation or by an enzymatic degradation and the cells are then re-plated on a fresh tissue culture medium. Colonies demonstrating undifferentiated morphology are individually selected by micropipette, mechanically dissociated into clumps, and re-plated. Resulting ES cells are then routinely split every 1-2 weeks. For further details on methods of preparation human ES cells see Thomson et al., [U.S. Pat. No. 5,843,780; Science 282: 1145, 1998; Curr. Top. Dev. Biol. 38: 133, 1998; Proc. Natl. Acad. Sci. USA 92: 7844, 1995]; Bongso et al., [Hum Reprod 4: 706, 1989]; Gardner et al., [Fertil. Steril. 69: 84, 1998].
It will be appreciated that commercially available stem cells can also be used with this aspect of the invention. Human ES cells can be purchased from the NIH human embryonic stem cells registry (<http://escr.nih.gov>). Non-limiting examples of commercially available embryonic stem cell lines are BG01, BG02, BG03, SA01, TE03 (I3), TE04, TE06 (I6), HES-1, HES-2, HES-3, UC01, UC06, WA01, WA07 and WA09 (see also Example 1 of the Examples section which follows).
Stem cells used by the present invention can be also derived from human embryonic germ (EG) cells and from induced pluripotent stem cells (Ips). Human EG cells are prepared from the primordial germ cells obtained from human fetuses of about 8-11 weeks of gestation using laboratory techniques known to anyone skilled in the arts. The genital ridges are dissociated and cut into small chunks which are thereafter disaggregated into cells by mechanical dissociation. The EG cells are then grown in tissue culture flasks with the appropriate medium. The cells are cultured with daily replacement of medium until cell morphology consistent with EG cells is observed, typically after 7-30 days or 1-4 passages. For additional details on methods of preparation human EG cells see Shamblott et al., [Proc. Natl. Acad. Sci. USA 95: 13726, 1998] and U.S. Pat. No. 6,090,622.
Regardless of their origin, stem cells used in accordance with the present invention are at least 50% purified, 75% purified or at least 90% purified. When human embryonic stem cell lines are used, the human ES cell colonies are separated from their feeder layer (x-ray irradiated fibroblast-like cells) such as by mechanical and/or enzymatic means to provide substantially pure stem cell populations.
Once human stem cells are obtained, they may be treated to differentiate into OPCs. An exemplary method is described in the Materials and Methods section below. It will be appreciated however, that the present method contemplates additional methods for generating OPCs, which are known in the art.
Thus, as described in Example 1 herein below, cells or aggregates thereof may be subjected to differentiation conditions, which comprise retinoic acids, such that neurospheres are allowed to form. The culture medium used is selected according to the stem cell used. Thus, for example, a medium suitable for ES cell growth, can be, for example, DMEM/F12 (Sigma-Aldrich, St. Lewis, Mo.) or alpha MEM medium (Life Technologies Inc., Rockville, Md., USA), supplemented with supporting enzymes and hormones. These enzymes can be for example insulin (ActRapid; Novo Nordisk, Bagsværd, DENMARK), progesterone and/or Apo transferrin (Biological Industries, Beit Haeniek, Israel). Other ingredients are listed in Example 1 of the Examples section.
As used herein the phrase “retinoic acid” refers to an active form (synthetic or natural) of vitamin A, capable of inducing neural cell differentiation. Examples of retinoic acid forms which can be used in accordance with the invention include, but are not limited to, retinoic acid, retinol, retinal, 11-cis-retinal, all-trans retinoic acid, 13-cis retinoic acid and 9-cis-retinoic acid (all available at Sigma-Aldrich, St. Lewis, Mo.).
In some embodiments of the invention retinoic acid is used at a concentration range of 1-50 μM.
The culture medium may be further supplemented with growth factors, which may be present at least in part of the culturing period to promote cell proliferation and facilitate differentiation into the neuronal glial lineages. According to an embodiment of this aspect of the present invention, such growth factors include for example, EGF (5-50 ng/ml) and bFGF (5-50 ng/ml) (R&D Systems, Minneapolis, Minn., Biotest, Dreieich, Germany).
As used herein the phrase “neurospheres” refers to quasi-spherical clusters or spheres containing mainly neural stem cells and early multipotent progenitors that can differentiate into neurons, oligodendrocytes and astrocytes as well as other glial cells.
The cells are cultured until ripened neurospheres are formed.
As used herein the phrase “ripened neurospheres” refers to neurospheres in which some of the neural stem cells have differentiated to become specialized oligodendrocyte progenitors having acquired makers of the oligodendrocyte lineage (e.g. Sox10, Nkx2.2., NG2, A2B5), while others have differentiated to become neural progenitors or astrocytes progenitors.
According to an embodiment of the invention the cells are allowed to culture, for example for 10-30 (e.g., 20-30) days, at the end of which detached neurospheres are formed. The spheres, or cells dissociated therefrom, are then adhered to adherent substrates (e.g. matrigel or an extracellular matrix component (e.g., collagen, laminin and fibronectin) and subjected to further expansion with growth factors and eventually to differentiation after removal of growth factors on a cationic adherent substrate (e.g. poly-D-lysine or Polyornithine with fibronectin (FN).
In order to avoid generation of terminally differentiated myelinating cells, the OPCs are not left at this stage in the absence of growth factors for more than three, four or five days.
Following neuroglial sphere formation (or concomitantly with) or following culture on adherent substrate, the cells may be incubated with an agent capable of inhibiting Bone Morphogenetic Protein (BMP) activity.
As used herein the term “agent capable of down-regulating BMP activity” refers to an agent which can at least partially reduce the function (i.e., activity and/or expression) of BMP.
BMP reducing agents include cystine knot-containing BMP antagonists, which are divided into three subfamilies, based on the size of the cystine ring; CAN (eight-membered ring), twisted gastrulation (nine-membered ring), and chordin and noggin (10-membered ring). The CAN family is divided further based on a conserved arrangement of additional cysteine residues, and includes gremlin and PRDC; cerberus and coco; DAN; USAG-1 and sclerostin.
Other BMP inhibitors include, but are not limited to, chordin like BMP inhibitor (CHL2), Neuralin (also homologous to chordin) which behave as secreted BMP-binding inhibitors; inhibin (belongs to the TGF-β superfamily); follistatin (which binds to inhibin); GDF3, an inhibitor of its own subfamily (TGF-β), which blocks classic BMP signaling in multiple contexts; Crossveinless-2 (hCV-2), a BMP function inhibitor; Ectodin (available at Qiagene, Valencia, Calif.), which is homologous to sclerostin and inhibits the activity of BMP2, BMP4, BMP6, and BMP7; connective tissue growth factor (CTGF), a BMP receptor antagonist; BMP-3, a BMP receptor antagonist; and gp130 signaling cytokines.
It will be appreciated that oligonucleotide inhibitors, which down-regulate expression of BMP genes (e.g., siRNA) may also be used in accordance with this aspect of the present invention. Methods of genetically modifying stem cells are well known in the art.
In one embodiment of this aspect of the present invention the agent used to inhibit BMP is noggin (e.g., 10-100 ng/ml, e.g., 50 ng/ml used as a Noggin-Fc chimera available from R&D systems, Minneapolis, N. Mex.). As mentioned, noggin can be used in any culturing step following, and optionally with retinoic acid treatment.
The time and period of treatment with the BMP inhibitor following neurosphere formation affects the differentiation level of the cells. The amount and timing of noggin culture may be adjusted so as to generate OPCs at a particular differentiation stage.
Noggin may also be added during the ripening of Neuro Spheres (NS).
The cells used for the assay of the present invention may be freshly generated or frozen cells. Typically, if the cells are frozen they are thawed in medium comprising growth factors (e.g. bFGF and EGF). The cells are typically cultured for at least one day following thawing in the absence of growth factors prior to the start of the assay.
Agents which may be tested using the assay of the invention include small molecule agents, chemicals, peptides, proteins, polynucleotide agents (e.g. siRNA agents). It will be appreciated that agents which are already known to affect myelination may also be used in this assay in order to quantify their optimum dose.
Contacting the cells with the agent can be performed by any in-vitro method known in the art including for example, adding the agent to the cells such that the agent is in direct contact with the cells. According to some embodiments of the invention, the cells of the subject are incubated with the agent. The conditions used for incubating the cells are selected for a time period/concentration of cells/concentration of agent/ratio between cells and agent and the like, which enable the agent to induce cellular changes, such as changes in transcription and/or translation rate of specific genes, which are analyzed. According to a specific embodiment, the cells are contacted with the agent for at least 3 days, 5 days, 7 days, 10 days, 14 days or at least 21 days.
Quantifying the effect of agents refers to the capability to grade the ability of the agent to affect myelination using a numerical value as opposed to determine whether the agent is simply able to affect myelination or not.
The quantification may be determined either by analyzing the number of cells which show the myelinating phenotype or by quantifying the amount of myelination on a particular number of cells (e.g. by determining the level of expression of a myelinating marker).
In order to perform the assay in a quantitative way, care should be taken when seeding the cells, such that the same number of cells is added to each assay dish and well. According to a specific embodiment, a 96 well plate is used to culture the OPCs. An exemplary number of OPCs to seed in one well of a 96 well plate is at least 5000. According to another embodiment, each dish or well of a 96 well plate is coated with Matrigel and PDL.
According to one embodiment, quantitative assessment of an agent may be effected by analyzing an expression level of a marker of myelination—such markers included myelin basic protein (MBP), myelin oligodendrocyte glycoprotein (MOG), myelin associated glycoprotein (MAG), galactocerebroside and/or proteolipid protein (PLP). Typically, an increase in expression of any of these markers in the human oligodendrocyte is indicative of an agent which increases (either an increase in the total number of cells which express and/or an increase in the level of expression) the myelination potential of the OPCs.
Quantitative measurement of expression levels of the above identified markers (and/or additional markers as further described herein below) may be effected using methods known in the art including, RT-PCR analysis, Western Blot analysis and immunohistochemistry.
Another method of quantifying a marker of myelination is by counting the number and/or measuring length of the OPC processes and/or counting the number of branch points in the OPCs. This may be performed using an antibody which recognizes OPCs such as an antibody which recognizes O4, 2′-5′ Cyclic Nucleotide 3′ phosphodiesterase (CNPase), as well as transcription factors olig1 and olig 2.
According to a preferred embodiment, immunohistochemistry methods are used such that additional cell parameters as well as expression of a myelinating marker may be studied.
Typically, the method requires the use of an antibody, which specifically recognizes the marker, wherein the antibody includes a detectable marker. Such markers include but are not limited to fluorescent moieties, peroxidase moieties, biotin moieties and phosphorescent moieties. Examples of antibodies which may be used in the context of the present assay are provided in the Examples section herein below. Anti-galactocerebroside antibodies are commercially available, for example, from Sigma.
In order to quantitatively analyze the effect of an agent on the myelinating potential of the OPCs, typically the percentage of cells in a particular field which express the marker of myelination is estimated. In some cases, only cells which co-express both a marker of myelination and a nuclear marker are counted (e.g. DAPI).
Many methods are known in the art to count the total number of cells per well or per field including but not limited to DAPI staining or Hoecht staining.
According to a particular embodiment of the invention, the number of O4/MBP positive processes are counted and measured only if attached to O4/MBP cell body. According to another embodiment, the lengths of the OPC processes are counted. Alternatively, or additionally, the number of branch points per O4 or MBP positive cell body is counted.
As well as (or instead of) analyzing markers of myelination in the OPCs of the invention, the present inventors also contemplate adding neuronal cells to the assay system so that the functional activity (i.e. myelinating potential) of the OPCs may be measured directly.
Any neuronal cells are contemplated by the invention as long as they are capable of being myelinated by oligodendrocytes.
According to a particular embodiment, mouse dorsal root ganglion cells are used. Such cells may be dissociated from mouse embryo (e.g. embryonic day 13 (E13)) and seeded on plates. The neuronal cells may be grown in the appropriate medium (e.g. Neurobasal (NB) medium).
In some embodiments of the invention, the neuronal cells are treated so as to eliminate Schwann cells and fibroblasts from the culture e.g. treatment with 10 μM uridine/10 μM 5′-Fluoro 2′-deoxyuridine (Sigma) to eliminate fibroblasts and Schwann cells.
Once sufficient neuronal cells are obtained, OPCs (preferably those which have been deprived of growth factors for 1-3 days) may be seeded thereupon. According to a particular embodiment, NB/N2B27 medium (1v/1v) supplemented with VitC (e.g. 50 μg/ml) may be used for the co-culture.
Following seeding, (e.g. 12-24 hours later), the agent may be added to the culture and after an appropriate amount of time (e.g. 4-45 days), the culture is analyzed.
According to this embodiment, the number of neuronal cells which are wrapped by myelin are counted (e.g. by counting the number of neuronal cells which are ensheathed by MBP positive or O4 positive cells which form myelin fibers).
Cells staining positively for proteins known to be adjacent to the nodes may be visualized, such as contactin associated protein, Caspr1 (contactin-associated protein 1) may also be counted. Expression of such proteins suggests that the in-vitro myelination reproduces the structure of myelin internodes and paranodes, since the condensation of Caspr at the paranode indicates a functional organization of node of Ranvier, necessary for rapid current conduction along the axon—see for example, Example 3 herein below.
Quantifying the amount of myelination in the neuronal cells may also be performed by analyzing a juxtaposition of the neuronal cells and myelinating cells.
Thus, neuronal cells staining positively for neurofilament proteins may be counted only when it is evident that they are ensheathed in MBP or O4 positive cells—see for example, Example 4 herein below.
It will be appreciated that computer programs may be used to integrate the data obtained from the immunohistochemistry analysis. Such programs are commercially available or may be produced in house by those skilled in the art.
The present inventors have found that enrichment of myelin producing cells may be performed by selecting for CD140a (PDGFRA) positive hESC derived OPC or O4 positive hESC derived OPC.
Typically, the selecting is effected using antibodies that are capable of specifically recognizing these cell-surface proteins, although the present invention contemplates additional agents such as polynucleotides or small molecules.
The enriching may be effected using known cell sorting procedures such as by using a fluorescence-activated cell sorter (FACS).
As used herein, the term “flow cytometry” refers to an assay in which the proportion of a material (e.g. OPC comprising a particular maker) in a sample is determined by labeling the material (e.g., by binding a labeled antibody to the material), causing a fluid stream containing the material to pass through a beam of light, separating the light emitted from the sample into constituent wavelengths by a series of filters and mirrors, and detecting the light.
A multitude of flow cytometers are commercially available including for e.g. Becton Dickinson FACScan and FACScalibur (BD Biosciences, Mountain View, Calif.). Antibodies that may be used for FACS analysis are taught in Schlossman S, Boumell L, et al, [Leucocyte Typing V. New York: Oxford University Press; 1995] and are widely commercially available.
If the CD140a or O4 antibody is attached to a magnetic moiety (either directly, or indirectly through a cognate binding molecule), the heterogeneous cell population may be enriched for cells by magnetic activated cell separation.
If the CD140a or O4 antibody is attached to an affinity moiety, the heterogeneous cell population may be enriched for CD140a or O4+ cells by affinity purification with the cognate binding molecule. Thus, for example, if the CD140a or O4 antibody is attached to biotin, the heterogenous cell population may be depleted of CD140a or O4+ by purification with Streptavidin beads or column. The CD140a or O4+ cells can subsequently be retrieved. If, for example the CD140a or O4+ antibody is attached to an antibody or an Fc of an antibody, the heterogeneous cell population may be depleted of CD140a or O4+ by purification with protein A beads or column. The CD140a or O4+ cells can subsequently be retrieved.
It will be appreciated that since the differentiated cells of this aspect of the present invention typically grow as adherent clusters, prior to cell sorting the heterogenous cell population should be dispersed using a dispersing agent.
Examples of dispersing agents include, but are not limited to dispase, collagenase, accutase and trypsin. Alternatively, or additionally trituration may also be performed to increase the dispersal of the cells.
Once a novel candidate agent shows that it is capable of up-regulating the myelinating potential of OPCs, their maturation or survival in the presently described assay, its optimal dose may be tested using the same in-vitro tests. The candidate agent's myelinating potential may also be tested in animal models for diseases associated with reduced myelination such as animal models for Multiple Sclerosis (such as mice treated with antigens to become Experimental Autoimmune Encephalitis (EAE) mice).
Once its pro-myelination, maturation or survival potential has been corroborated, the agent may be synthesized in commercial amounts and/or pharmaceutical compositions comprising same may be synthesized, as described herein below.
As used herein a “pharmaceutical composition” refers to a preparation of one or more of the active ingredients described herein with other chemical components such as physiologically suitable carriers and excipients. The purpose of a pharmaceutical composition is to facilitate administration of a compound to an organism.
Herein the term “active ingredient” refers to the agent which upregulates myelination, maturation or survival accountable for the biological effect.
Hereinafter, the phrases “physiologically acceptable carrier” and “pharmaceutically acceptable carrier” which may be interchangeably used refer to a carrier or a diluent that does not cause significant irritation to an organism and does not abrogate the biological activity and properties of the administered compound. An adjuvant is included under these phrases.
Herein the term “excipient” refers to an inert substance added to a pharmaceutical composition to further facilitate administration of an active ingredient. Examples, without limitation, of excipients include calcium carbonate, calcium phosphate, various sugars and types of starch, cellulose derivatives, gelatin, vegetable oils and polyethylene glycols.
Techniques for formulation and administration of drugs may be found in “Remington's Pharmaceutical Sciences,” Mack Publishing Co., Easton, Pa., latest edition, which is incorporated herein by reference.
The agents identified using the assay of the present invention may be used in the ex-vivo generation of myelinating cells from stem cells. Alternatively, the agents may be administered directly to a patient suffering from a disease associated with lack of myelination. Such diseases include, but are not limited to multiple sclerosis, acute disseminated encephalomyelitis, transverse myelitis, chronic inflammatory demyelinating polyneuropathy, Guillain-Barré Syndrome, central pontine myelinosis, inherited demyelinating diseases such as Leukodystrophy, and Charcot Marie Tooth.
As used herein the term “about” refers to ±10%.
The terms “comprises”, “comprising”, “includes”, “including”, “having” and their conjugates mean “including but not limited to”.
The term “consisting of” means “including and limited to”.
The term “consisting essentially of” means that the composition, method or structure may include additional ingredients, steps and/or parts, but only if the additional ingredients, steps and/or parts do not materially alter the basic and novel characteristics of the claimed composition, method or structure.
Throughout this application, various embodiments of this invention may be presented in a range format. It should be understood that the description in range format is merely for convenience and brevity and should not be construed as an inflexible limitation on the scope of the invention. Accordingly, the description of a range should be considered to have specifically disclosed all the possible sub-ranges as well as individual numerical values within that range. For example, description of a range such as from 1 to 6 should be considered to have specifically disclosed sub ranges such as from 1 to 3, from 1 to 4, from 1 to 5, from 2 to 4, from 2 to 6, from 3 to 6 etc., as well as individual numbers within that range, for example, 1, 2, 3, 4, 5, and 6. This applies regardless of the breadth of the range.
Whenever a numerical range is indicated herein, it is meant to include any cited numeral (fractional or integral) within the indicated range. The phrases “ranging/ranges between” a first indicate number and a second indicate number and “ranging/ranges from” a first indicate number “to” a second indicate number are used herein interchangeably and are meant to include the first and second indicated numbers and all the fractional and integral numerals there between.
As used herein the term “method” refers to manners, means, techniques and procedures for accomplishing a given task including, but not limited to, those manners, means, techniques and procedures either known to, or readily developed from known manners, means, techniques and procedures by practitioners of the chemical, pharmacological, biological, biochemical and medical arts.
It is appreciated that certain features of the invention, which are, for clarity, described in the context of separate embodiments, may also be provided in combination in a single embodiment. Conversely, various features of the invention, which are, for brevity, described in the context of a single embodiment, may also be provided separately or in any suitable sub-combination or as suitable in any other described embodiment of the invention. Certain features described in the context of various embodiments are not to be considered essential features of those embodiments, unless the embodiment is inoperative without those elements.
Various embodiments and aspects of the present invention as delineated hereinabove and as claimed in the claims section below find experimental support in the following examples.
EXAMPLESReference is now made to the following examples, which together with the above descriptions illustrate some embodiments of the invention in a non-limiting fashion.
Generally, the nomenclature used herein and the laboratory procedures utilized in the present invention include molecular, biochemical, microbiological and recombinant DNA techniques. Such techniques are thoroughly explained in the literature. See, for example, “Molecular Cloning: A laboratory Manual” Sambrook et al., (1989); “Current Protocols in Molecular Biology” Volumes I-III Ausubel, R. M., ed. (1994); Ausubel et al., “Current Protocols in Molecular Biology”, John Wiley and Sons, Baltimore, Md. (1989); Perbal, “A Practical Guide to Molecular Cloning”, John Wiley & Sons, New York (1988); Watson et al., “Recombinant DNA”, Scientific American Books, New York; Birren et al. (eds) “Genome Analysis: A Laboratory Manual Series”, Vols. 1-4, Cold Spring Harbor Laboratory Press, New York (1998); methodologies as set forth in U.S. Pat. Nos. 4,666,828; 4,683,202; 4,801,531; 5,192,659 and 5,272,057; “Cell Biology: A Laboratory Handbook”, Volumes I-III Cellis, J. E., ed. (1994); “Culture of Animal Cells—A Manual of Basic Technique” by Freshney, Wiley-Liss, N. Y. (1994), Third Edition; “Current Protocols in Immunology” Volumes I-III Coligan J. E., ed. (1994); Stites et al. (eds), “Basic and Clinical Immunology” (8th Edition), Appleton & Lange, Norwalk, Conn. (1994); Mishell and Shiigi (eds), “Selected Methods in Cellular Immunology”, W. H. Freeman and Co., New York (1980); available immunoassays are extensively described in the patent and scientific literature, see, for example, U.S. Pat. Nos. 3,791,932; 3,839,153; 3,850,752; 3,850,578; 3,853,987; 3,867,517; 3,879,262; 3,901,654; 3,935,074; 3,984,533; 3,996,345; 4,034,074; 4,098,876; 4,879,219; 5,011,771 and 5,281,521; “Oligonucleotide Synthesis” Gait, M. J., ed. (1984); “Nucleic Acid Hybridization” Hames, B. D., and Higgins S. J., eds. (1985); “Transcription and Translation” Hames, B. D., and Higgins S. J., eds. (1984); “Animal Cell Culture” Freshney, R. I., ed. (1986); “Immobilized Cells and Enzymes” IRL Press, (1986); “A Practical Guide to Molecular Cloning” Perbal, B., (1984) and “Methods in Enzymology” Vol. 1-317, Academic Press; “PCR Protocols: A Guide To Methods And Applications”, Academic Press, San Diego, Calif. (1990); Marshak et al., “Strategies for Protein Purification and Characterization—A Laboratory Course Manual” CSHL Press (1996); all of which are incorporated by reference as if fully set forth herein. Other general references are provided throughout this document. The procedures therein are believed to be well known in the art and are provided for the convenience of the reader. All the information contained therein is incorporated herein by reference.
Materials and Methods
Generation of Cells Used for the Assay
Human ES cell lines were cultured at 37° C. in 5% CO2 on feeder layers of human new-born foreskin fibroblasts (HEF). The growth medium (ES1) consisted of DMEM/F12 (Sigma), 14% knockout serum replacement (KSR), nonessential amino acids (1/100), 100 mM beta-mercaptoethanol (all three from Invitrogen/Gibco), 1 mM Na pyruvate, 2 μg/ml heparin (Sigma) and 8 ng/ml human recombinant basic FGF (FGF-2; Preprotech). Five days after seeding, hES cell colonies were detached with 1.2 mg/ml collagenase IV (Worthington) for 45-90 minutes at 37° C. The aggregates were further cultured as above, or subjected to differentiation as described (Izrael et al Mol Cell Neurosci 34, 310-323 (2007)).
Step 1—Transition:
For this transition step, hES cell colonies were transferred to tissue culture plates in medium T (Transition) consisting of 50% (v/v) ES1 medium and 50% (v/v) of ITTSPP/B27medium. ITTSPP/B27 is itself a mixture of one volume of DMEM/F12 containing 2% B27 supplement (Invitrogen) and one volume of DMEM/F12 containing 25 μg/ml human insulin (ActRapid, Novo Nordisk), 50 μg/ml human Apo-transferrin (Biological Industries, Israel), 6.3 ng/ml progesterone, 10 μg/ml putrescine, 50 ng/ml sodium selenite and 40 ng/ml triiodothyronine (T3) (all from Sigma), with 100 U/ml penicillin and 100 μg/ml streptomycin. Medium T was supplemented by 20 ng/ml r-human EGF (R&D Systems) and 4 ng/ml r-human bFGF. After 1 day, the bulk of non-adherent hES cells colonies and aggregates were transferred to 6 cm bacterial (non-adherent) plates and grown in T medium supplemented with 20 ng/ml r-human EGF (R&D Systems) and 2 ng/ml r-human bFGF.
Step 2: All-Trans Retinoic Acid (ATRA) Treatment:
The medium was switched to ITTSPP/B27, with 20 ng/ml EGF and 10 mM ATRA additions. Medium was changed daily for 7 days.
Step 3: Suspension Culture:
During this step, which allows for ripening of neurospheres (NS), the culture was continued in ITTSPP/B27 medium with 20 ng/ml EGF for 18 days. Medium was changed every other day.
Neural stem cells proliferation and differentiation
Step 4: Matrigel Adhesion 1:
Spheres/clusters were transferred to 6-well tissue culture plates that had been coated for 1.5 h at room temperature (RT) with BD Matrigel (growth factor reduced Matrigel, BD Biosciences) diluted 1:30 in DMEM/F12. The culture medium was ITTSPP/B27 with 20 ng/ml EGF and after one day, any non-adherent aggregates were discarded. Medium was changed every other day for 7-9 days.
Step 5: Matrigel Adhesion 2:
The neurospheres/clusters which were free from fibroblast and epithelial cells were selected and picked on a new Matrigel plate. Neurospheres (not more than 10 NS) were detached and partially dissociated with 0.025% trypsin (InVitrogen) in PBS (Ca+ and Mg2+ free), for 2-3 min at 37° C. (passage 1). The trypsin was neutralized by one volume of trypsin inhibitor (Invitrogen) and four volumes of 2 mg/ml BSA in ITTSPP/B27. The cells were spun at 1200 rpm for five minutes in an Eppendorf centrifuge. The dissociated small clusters were re-seeded onto Matrigel-coated plates (at 1:1 to 1:3 ratio) in ITTSPP/B27 with 20 ng/ml EGF (step 4). After 2-3 weeks, the cells were dissociated by trypsin treatment as above (passage 2) and the resulting hES-NS cells were seeded on plates coated with poly-D-lysine (PDL, 100 μg/ml) and mouse laminin (20 μg/ml) or PDL (20 μg/ml) and fibronectin 5 μg/ml in ITTSPP/B27 with 20 ng/ml EGF, for one day. At each new seeding, 1 μg/ml mouse laminin (Sigma) was added to the medium.
Steps 6 and 7: Expand on Poly-D-Lysine:
After one day, the medium was changed to N2/B27 medium consisting of DMEM/F12 with 0.5% (v/v) N2 supplement (Invitrogen), 1% (v/v) B27 supplement. Growth factors EGF and bFGF were added at 10 ng/ml each. After 7-14 days, the cells from PDL plates were split (1:2 or 1:3, passage 2 (P2)) by trypsinization to obtain monolayers. After one week, cells were collected with trypsin and frozen in 0.5×106 cells ampoule (P3). Further passages were conducted weekly, when indicated.
Step 8: GF Removal:
At different passages, the terminal differentiation was initiated by removing the growth factors. Whenever growth factors were removed, 1 μg/ml mouse laminin, 50 ng/ml noggin and 50 μg/ml vitamin C were added to the N2/B27 medium. Cells were thawed in N2/B27 medium supplemented with growth factors bFGF and EGF. One day before splitting and seeding in 96 well plates, growth factors were removed.
Differentiation Assay; Dose Response of Noggin
5000 hES-OPC were seeded in each well of Matrigel and PDL-coated 96 well black clear plates (CI-3603, Corning). The medium used for the experiment comprised DMEM/F12 with 0.5% (v/v) N2 supplement (Invitrogen), 1% (v/v) B27 supplement, Glutamax and 100 U/ml penicillin and 100 μg/ml streptomycin (Biological Industries, IL). The cells were deprived from growth factors 24 hours prior to seeding. 12 hours following seeding, increasing doses of Noggin (Preprotech, Israel) were supplemented to the media for the ten days of differentiation. The Noggin doses ranged between 15 nM to 0.015 nM (450 ng/ml to 0.45 ng/ml) with 3.16 fold dilutions (square root of 10) in the presence of 0.1% DMSO and 50 μg/ml Vitamin C. Samples without Noggin in the presence of 0.1% DMSO and 50 μg/ml Vitamin C served as negative control. The media was changed every other day by replenishing ⅔ of the media. On day ten, the wells were fixed using 4% paraformaldehyde (PFA) for further O4 and Dapi staining.
Co-culture between DRG neurons and hES-OPC
Mouse DRG Neuron Purification:
DRG dissociated cells from mouse embryonic day 13 (E13) were seeded on matrigel and PDL-coated 12 well plates (30,000 cells/well) or seeded on 96 well black clear plates (CI-3603, Getter) (7000 cell/well) and grown in NB medium for two weeks prior hES-OPC addition. NB media consist of Neurobasal medium (Gibco) supplemented with B27 (Gibco) and 50 ng/ml NGF (Alomone labs). At the first week of DRG culture, the cells were treated with two cycles (two days each) of NB medium containing 10 μM uridine/10 μM 5′-Fluoro 2′-deoxyuridine (Sigma) to eliminate fibroblasts and Schwann cells.
Co-Culture with hES-OPC:
Following two weeks of DRG neuron culture, 50,000 (on 12 well plate) or 10,000 (on 96 well plate) hES derived-OPC that were grown in the absence of GF for 3 days were seeded on DRG neurons. The co-culture was conducted in NB/N2B27 medium (1v/1v) supplemented with VitC 50 μg/ml, NGF was omitted from DRG neurons culture medium, two days prior hES-OPC addition. Co-cultures were fixed and RNA extraction and immunohistochemistry (IHC) were conducted at different time points in order to evaluate differentiation and myelination.
Myelination Assay-Dose Response of Gamma Secretase Inhibitor X:
hES-OPCs which were deprived from growth factors (EGF and bFGF) for one day were seeded on top of DRGs neurons. 12 hours after seeding, increasing doses of gamma secretase inhibitor X (GSI-X, MBS565771, Calbiochem) were supplemented to the media for the 21 days of differentiation. GSI-X doses ranged between 1 nM to 1 μM with 3.16 folds (square root of 10) in the presence of 0.1% DMSO and 50 μg/ml Vitamin C. Wells without GSI with 0.1% DMSO and 50 μg/ml Vitamin C served as a control. The media was changed every other day by replenishing ⅔ of the media. On day 21 the wells were fixed using 4% PFA for further MBP, Neurofilament-160 kd and Dapi staining (detailed below).
Gene Expression Analysis
RNA and Gene Expression Analysis:
Total RNA was isolated using RNeasy (Qiagen) and cDNA transcribed with reverse transcriptase RT M-MLV (Promega) or Superscript II (Invitrogen). The PCR reactions were conducted with Super Therm Taq polymerase. The primers sequences of oligodeoxynucleotide for each of the indicated genes are provided in Table 1, herein below. The PCR conditions were as followed; amplification: 94° C., 2 minutes then 30 cycles (except 22 cycles for GAPDH) at 94° C., 30 seconds; 52-58° C., 30 seconds; 72° C., 1 minute. The amplified DNA bands were photographed under UV-light, scanned, and their intensity was quantified using the AlphaEase spot density software. Band intensity was verified to be in the linear range by varying the amount of PCR reaction loaded on the gels.
Microarrays:
Total RNA was extracted using the RNneasy micro kit (Qiagen, Valencia, Calif.). The quality of total RNA was assessed using RNA 6000 Nano LabChip (Agilent Technologies, CA, USA) and Bio-analyzer microchip (Agilent Technologies, CA, and USA). Two independent biological replicates of RNA extracts for each experimental condition were used to prepared cDNA and biotin-labeled cRNA for hybridization. DNA microarray analyses were carried out with Affymetrix Human Gene 1.0 ST array according to the Affymetrix standard protocol (Affymetrix, Santa Clara, Calif.). Fold induction analysis performed with MAS 5 statistical algorithms at the Crown Human Genome Center, Weizmann Institute of Science.
Immunostaining:
Cells were fixed using 4% paraformaldehyde (PFA), washed with PBS and kept at 4° C. before staining. Non-specific staining was blocked with normal goat serum (5% w/v in PBS) for 30 minutes at RT. Primary mouse monoclonal (mMc) and rabbit polyclonal antibodies, diluted in 1% goat serum, were as described in Table 2, herein below. All staining was followed by the nuclear fluorescent dye DAPI (Sigma, 0.05 μg/ml). All coverslips were mounted in Mowiol (Calbiochem, La Jolla, Calif.). An Olympus IX-70 FLA microscope with a DVC-1310C digital camera (DVC, Austin, Tex.) was used and images processed with Photoshop and analyzed with Image-Pro-Plus software (Media Cybernetics, Silver Spring, Md.) to measure Integrated Optic Density (IOD) of color-specific pixels and MBP positive fiber length. HSC Scan-Array VTI (Cellomics, Thermo-dynamics) was used for scanning and processing the images of O4 positive cells by using the neural profiling module. Statistical analyses by two-tailed Student t-test and ANOVA were with Instat (GraphPad Software Inc., San Diego, Calif.) or JMP 5.0 software (SAS Institute, Cary, N.C.).
Magnetic Activated Cell Sorting (MACS) with O4 Microbeads:
107 hOPCs were incubated with conjugated anti-O4 microbeads (Miltenyi Biotec, 130-094-543, 10 μl) for 15 minutes at 4° C., according to the manufacturer's protocol. The cells were washed by adding 2 ml of phosphate-buffered saline (PBS), PH 7.2, and 0.5% bovine serum albumin (BSA) and centrifuged at 300×g for ten minutes. The supernatant was aspirated completely and up to 107 cells were re-suspended in 500 μl of buffer.
The magnetic separation was conducted using MS column and miniMACS separator (Miltenyi Biotec,) according to the manufacturer's protocol.
Magnetic Activated Cell Sorting (MACS) with CD140a+:
107 hOPCs were incubated with Human Anti Alpha PDGFR-PE-100T (BD, PMG556002, 10 μl) for 15 minutes at 4° C. according to the manufacturer's protocol. The cells were washed by adding 2 ml of phosphate-buffered saline (PBS), PH 7.2, and 0.5% bovine serum albumin (BSA) and centrifuged at 300×g for ten minutes. The supernatant was aspirated completely and up to 107 cells were re-suspended in 80 μl of buffer.
Anti-PE microbeads (Miltenyi Biotec, 130-048-801, 20 μl) were added to 107 cells and incubated for 15 minutes at 4° C. The cells were washed by adding 2 ml of phosphate-buffered saline (PBS), PH 7.2, and 0.5% bovine serum albumin (BSA) and centrifuged at 300×g for 10 minutes. The supernatant was aspirated completely and up to 108 cells were re-suspended in 500 μl of buffer.
The magnetic separation was conducted using LS column and miniMACS separator (Miltenyi Biotec,) according to the manufacturer's protocol.
FACS Analysis of Pre-Sorted Cells, Sorted Cells and the Negative Cell Population:
1×105 (100 μl) of pre-sorted cells, sorted cells and the negative cell population were transferred to Eppendorf tubes for FACS analysis. For each sample (10-20 μl) of the primary antibody were added (Anti-O4-APC, Miltenyi Biotec, 130-095-891) and incubated at 4° C. for 30 minutes. The cells were washed by adding FACS buffer (Ca2+ and Mg2+-free PBS with 0.2-2% BSA or HSA) to bring cell suspension to 1.3 ml. The cells were centrifuge at 1680 RPM (300 g) for five minutes at 4° C., re-suspended in 200 μl FACS buffer, passed into FACS tubes through their mesh and analyzed on the flow cytometer (BD Biosciences, Mountain View, Calif.) according to the manufacturer's protocol.
Example 1 Generation and Characterization of Cells Used in the Myelination AssayThe human ES cells were differentiated by a stepwise protocol, where neural spheres develop and grow in suspension with EGF. Neural spheres cells were then separated from non-neural tissues by attachment to Matrigel extracellular matrix and growth with EGF. To investigate the effect of drugs on oligodendrocyte function, it is important to use well-characterized pools of human oligodendrocyte progenitor cells that may be differentiated by a simple procedure in-vitro or in-vivo. Proliferation of neural sphere cells, dissociated with trypsin, on Poly D-Lysine-coated plates for two to three passages in the presence of growth factors EGF and bFGF, yields lines of neural stem cells (NSC) available for further differentiation studies. Each line results from the dissociation of pools of neural spheres.
In-vitro and in-vivo, CNS OLs develop from NSC through a series of morphological steps, as summarized in
Two NSC lines were characterized more thoroughly by analysis of gene expression levels on human cDNA microarrays (Affymetrix). cDNA was derived from duplicate samples of NSCs, grown in the presence or absence of growth factors for three days. Genes expressed in the cells were compared with sets of genes that do not overlap one with the other and neurons, astrocytes and oligodendrocytes were characterized. The results show that NSCs proliferating in the presence of growth factors (left lanes) express only 4-5 out of 27 genes characterizing either astrocytes or oligodendrocytes. After growth factor removal, cells differentiate and express 24 out of 27 genes characterizing astrocytes or oligodendrocytes (
BMP signaling negatively regulates oligodendrocyte lineage development, and it has been shown that Noggin, an inhibitor of BMP signaling, promotes the differentiation of ES-derived oligodendrocytes. As a proof of concept that effects of drugs on oligodendrocyte differentiation can be quantified, the inventors searched for the optimal concentration of Noggin to be used to promote differentiation. NSCs at fifth passage were distributed to wells of 96 well dishes and submitted to differentiation in the absence or the presence of Noggin in serial dilutions 1:3.16 at concentrations varying from 150 ng/ml to 0.5 ng/ml (4.7×10−9 to 1.5×10−11M) in triplicate assays. After ten days without growth factors, cells were stained with O4 monoclonal antibody, and nuclei counterstained with DAPI. Noggin added after growth factor removal stimulates the emergence of OLs with longer and multiple processes versus bipolar O4 positive cells in the absence of Noggin (
To address mechanistic aspects of myelination in the CNS, a system of co-cultures of purified neurons and oligodendrocytes was used.
Since the hES derived OPC can differentiate to mature oligodendrocytes, the inventors asked whether these cells can myelinate neurons in-vitro or in-vivo.
As targets of myelination, mouse embryonic dorsal root ganglia (DRG) neurons were used. The DRG neurons were obtained from mouse embryonic day 13 (E13) and seeded on Matrigel and PDL-coated plates. The neurons were cultured for two weeks in the presence of NGF, and during the first week two cycles of FuDR treatment eliminated Schwann cells from the culture. Pictures of the neurons, hOPC and co-culture of both are shown in
Triplicate of the co-culture experiments were treated with serial dilution of another gamma secretase inhibitor (gamma secretase inhibitor X, Calbiochem) in order to determine the effect of this inhibitor on oligodendrocyte differentiation.
After 21 days, the neurons were stained with anti neurofilament Ab (
In order to improve the yield of OPC and immature oligodendrocytes population in the hES-OPC culture, the cells were sorted with O4 microbead antibody. The sorting was conducted on hOPC that were deprived from growth factors (bFGF and EGF) and supplemented with Noggin. O4 expression was then detected by IHC and FACS techniques.
In order to test whether myelination can be improved by O4 sorting, the myelination capacity of hESC-OPC was compared with and without O4 sorting. As shown in
In order to improve the yield of OPC progenitor population in the hES-OPC culture, the cells were sorted with oligodendrocytes progenitor early marker CD140a (PDGFRa). This was conducted on hOPC that were deprived from growth factors (bFGF and EGF) and supplemented with Noggin. CD140a expression was then detected by IHC and FACS techniques.
Next, it was tested whether CD140a+ sorting improve the potential of cells to become myelinating MBP+ cells. A comparison between myelination capacity of hESC-OPC with and without CD140 sorting was conducted. For that aim presorted cells or CD140a+ sorted cells were co-culture with DRGs neuron axons.
In order to evaluate the survival of human oligodendrocytes or its progenitor cells in culture, a specific dead cell labeling (Live/dead viability/cytotoxicity kit for mammalian cells, Invitrogen, molecular probes, L3223) was used. A culture of differentiated oligodendrocytes and oligodendrocytes progenitor culture sorted by O4+ or CD140+ MACS sorting respectively were obtained. The effect of recombinant human IFN-Y (R&D systems, Biotest, 285-IF-100) was tested on oligodendrocytes survival. Following 14 days in culture the cells were labeled with dead cell labeling (Ethidium heterodimer 1-red labeling) and O4 labeling (green). It was found that IFN-Y increased the percentage of dead cells and decreased the number of differentiated oligodendrocytes (
Although the invention has been described in conjunction with specific embodiments thereof, it is evident that many alternatives, modifications and variations will be apparent to those skilled in the art. Accordingly, it is intended to embrace all such alternatives, modifications and variations that fall within the spirit and broad scope of the appended claims.
All publications, patents and patent applications mentioned in this specification are herein incorporated in their entirety by reference into the specification, to the same extent as if each individual publication, patent or patent application was specifically and individually indicated to be incorporated herein by reference. In addition, citation or identification of any reference in this application shall not be construed as an admission that such reference is available as prior art to the present invention. To the extent that section headings are used, they should not be construed as necessarily limiting.
Claims
1.-30. (canceled)
31. A method of making enriched oligodendrocyte precursor cells (OPCs), comprising:
- (a) culturing human embryonic stem cells (hES) in a medium comprising retinoic acid and Epidermal Growth Factor (EGF), thereby generating neurospheres;
- (b) contacting the neurospheres with an adherent substrate comprising an extracellular matrix;
- (c) following step (b), dissociating the neurospheres;
- (d) culturing the dissociated neurospheres in a medium comprising EGF and basic Fibroblast Growth Factor (bFGF);
- (e) following step (d), culturing the dissociated neurospheres in a medium lacking growth factors, thereby generating ex vivo differentiated neural cells;
- (f) selecting the ex vivo differentiated neural cells to be O4-positive or CD140-positive;
- (g) expanding, freezing, and thawing the selected neural cells in a medium comprising EGF and bFGF;
- (h) after thawing, culturing the selected neural cells for at least one day in a medium lacking growth factors; thereby making the enriched OPCs.
32. The method of claim 31, wherein the OPCs further express Hes5.
33. The method of claim 31, wherein the hES in step (a) are aggregated.
34. The method of claim 31, wherein the medium of step (a) further comprises noggin.
35. The method of claim 31, wherein the medium of step (e) comprises noggin.
36. The method of claim 31, wherein the selecting of step (f) is performed by magnetic sorting (MACS) or fluorescence activated cell sorting (FACS).
37. A method of quantifying an effect of an agent on myelination of OPCs or on maturation or survival of oligodendrocytes, or a combination thereof, comprising:
- (a) making enriched OPCs according to claim 31;
- (b) following step (a), contacting the enriched OPCs with the agent; and,
- (c) measuring the level of at least one of a marker of myelination, a marker of maturation or survival, or a combination thereof, in the cells following step (b), thereby quantifying the effect of the agent or myelination of OPCs, maturation or survival of oligodendrocytes, or a combination thereof.
38. The method of claim 37, wherein the quantifying further comprises comparing the level of the marker in step (c) to the level of the marker measured in control OPCs, oligodendrocytes, or combination thereof made according to the method of claim 31, wherein the control cells are not contacted with the agent.
39. The method of claim 37, wherein the marker is a polypeptide selected from the group consisting of myelin basic protein (MBP), myelin oligodendrocyte glycoprotein (MOG), galactocerebroside (GalC), myelin associated glycoprotein (MAG), 2′3′-cyclic nucleotide-30-phosphodiesterase (CNP), O4; and proteolipid protein (PLP).
40. The method of claim 37, wherein the quantifying comprises counting the number of O4 stained cells with at least two processes, calculating the percentage of O4 positive cells, counting the number of processes per O4 stained cells, measuring the total length of the processes per O4 stained cells, counting the number of branch points per O4 stained cells, counting the number of MBP positive cells, calculating the percentage of MBP positive cells, or measuring the area of myelin membranes per stained cells or the area of the O4 stained processes.
Type: Application
Filed: Jul 15, 2019
Publication Date: Jan 2, 2020
Applicant: KADIMASTEM, LTD. (Nes-Ziona)
Inventors: Michel Revel (Rehovot), Judith Chebath (Rehovot), Arye Hasson (Kiryat Ono), Michal Izrael (Rehovot), Rosalia Kaufman (Rehovot)
Application Number: 16/511,985
